The glycemic efficacy of tirzepatide in the treatment of T2DM was found to be due to simultaneous improvements in key components of diabetes pathophysiology, including beta-cell function, insulin sensitivity, and glucagon secretion, in Phase 1 clinical trials [131]. This evidence concerns the gene INS and diabetes mellitus.